EX-16.1 2 ea021144701ex16-1_nlspharma.htm LETTER FROM PRICEWATERHOUSECOOPERS AG. ADDRESSED TO THE U.S. SECURITIES AND EXCHANGE COMMISSION DATED AUGUST 15, 2024

Exhibit 16.1

 

 

August 15, 2024

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by NLS Pharmaceutics Ltd. pursuant to Item 304(a)(1) of Regulation S-K (copy attached), which we understand will be filed with the Securities and Exchange Commission on Form 6-K of NLS Pharmaceutics Ltd. dated August 15, 2024. We agree with the statements concerning our Firm contained therein.

 

Very truly yours,

 

/s/ PricewaterhouseCoopers AG

 

Zurich, Switzerland

 

Attachment

 

 

 

PricewaterhouseCoopers AG, Birchstrasse 160, Postfach, 8050 Zürich

T: +41 58 792 44 00, F: +41 58 792 44 10, www.pwc.ch

 

PricewaterhouseCoopers AG is a member of a global network of companies that are legally independent of one another.